Speaker Faculty

2024 World-Class Speaker Faculty:

Robbie McCarthy, Laurel Damashek 4th Rare & Genetic Kidney Disease Drug Development

Robbie McCarthy

Acting Head of Business Development

Advicenne S.A.

Andre Weinstock, 4th Rare & Genetic Kidney Disease Drug Development

B. André Weinstock

Director - Research

Alport Syndrome Foundation

Stephen Olson

Senior Director - Medical, Early Clinical Development, Cardiovascular, Renal & Metabolism

AstraZeneca

Weining Lu, 4th Rare & Genetic Kidney Disease Drug Development

Weining Lu

Associate Professor of Medicine

Boston University

Laurence Beck

Associate Professor of Medicine (Nephrology); physician

Boston University

Richard Watt, 4th Rare & Genetic Kidney Disease Drug Development

Richard Watt

Associate Professor - Department of Chemistry and Biochemistry, CSO Revitale Pharma

Brigham Young University & REVITALE Pharma

Achim Obergfell, 4th Rare & Genetic Kidney Disease Drug Development

Achim Obergfell

Global Medical Head of Nephrology

CSL Vifor

Doug Paul, 4th Rare & Genetic Kidney Disease Drug Development

Doug Paul

VP Commercial Strategy & Founder

Cypress BioPharma

Sumit Aggarwal, 4th Rare & Genetic Kidney Disease Drug Development

Sumit Aggarwal

Chief Executive Officer & President

Eloxx Pharmaceuticals

Pete Leone 4th Rare & Genetic Kidney Disease Drug Development

Pete Leone

Head of Business Development & Licensing

ENYO Pharma

Aliza Thompson, Rare & Genetic Kidney Disease Drug Development Summit 2024

Aliza Thompson

Acting Director

Division of Cardiology and Nephrology, CDER, FDA

Lynne Yao

Associate Director - Division of Pediatrics & Maternal Health

FDA

Balaji Subramanian, 4th Rare & Genetic Kidney Disease Drug Development

Balaji Karthick Subramanian

Assistant Professor of Medicine

Harvard Medical School

Dongwon Lee

Assistant Professor of Pediatrics

Harvard Medical School

Friedhelm Hildebrandt, 4th Rare & Genetic Kidney Disease Drug Development

Friedhelm hildebrandt

Chief of Nephrology

Harvard Medical School

Dario Lemos, 4th Rare & Genetic Kidney Disease Drug Development

Dario Lemos

Assistant Professor of Medicine

Harvard Medical School & Brigham and Women's Hospital

Neel Anand

Senior Vice President - Research & Drug Discovery

Kezar Life Sciences

Susan Limb, 4th Rare & Genetic Kidney Disease Drug Development

Susan Limb

Vice President, Clinical Science

Maze Therapeutics

Laurel Damashek 4th Rare & Genetic Kidney Disease Drug Development

Laurel Damashek

Executive Director

International Society of Glomerular Disease

Bryce Powerman 4th Rare & Genetic Kidney Disease Drug Development

Bryce Powerman

Director of Business Development

Natera

Adele Rowley, 4th Rare & Genetic Kidney Disease Drug Development

Adele Rowley

Chief Scientific Officer

Mironid Ltd.

David Feldman, 4th Rare & Genetic Kidney Disease Drug Development

David Feldman

Senior Medical Project director

National Kidney Foundation

William Smoyer, 4th Rare & Genetic Kidney Disease Drug Development

William Smoyer

Vice President - Clinical & Translational Research

Nationwide Children's Hospital

Josh Tarnoff, 4th Rare & Genetic Kidney Disease Drug Development

Joshua Tarnoff

Chief Executive Officer

NephCure Kidney International

Jee Yeon Kim, 4th Rare & Genetic Kidney Disease Drug Development

Jee Yeon Kim

Associate Clinical Research Medical Director (Renal)

Novartis AG

Srini Srinivas, 4th Rare & Genetic Kidney Disease Drug Development

Srini Srinivas

Senior Medical Director, Renal Diseases & Evidence Generation Lead

Novartis AG

Gerard Honig, 4th Rare & Genetic Kidney Disease Drug Development

Gerard Honig

Associate Director - Biomarker Research

Otsuka Pharmaceutical Development & Commercialization, Inc

Michelle Richardson, 4th Rare & Genetic Kidney Disease Drug Development

Michelle Richardson

Associate Director, Patient-Centered Research & Clinical Outcome Assessments

Otsuka Pharmaceuticals Development & Commercialization, Inc

Pille Harrison, 4th Rare & Genetic Kidney Disease Drug Development

Pille harrison

Vice President, Clinical Development

Purespring Therapeutics

John Seman, 4th Rare & Genetic Kidney Disease Drug Development

John Seman

Chief Executive Officer

REVITALE Pharma

Chris Smith, 4th Rare & Genetic Kidney Disease Drug Development

Chris Smith

President & CEO

SmithSolve LLC

Rachel McComb, 4th Rare & Genetic Kidney Disease Drug Development

Rachel McComb

Senior Manager, Clinical Operations Program Lead

Takeda Pharmaceutical Co. Ltd.

Sean Eddy, 4th Rare & Genetic Kidney Disease Drug Development

Sean Eddy

Assistant Scientist - Research

University of Michigan

Eloise Salmon, 4th Rare & Genetic Kidney Disease Drug Development

Eloise Salmon

Clinical Assistant Professor

University of Michigan

Kerry Cooper

Senior Vice President Medical Affairs

Vera Therapeutics

Alex Duncan, 4th Rare & Genetic Kidney Disease Drug Development

Alex Duncan

Chief Scientific Officer

Walden Biosciences

Allen Davidoff, 4th Rare & Genetic Kidney Disease Drug Development

Allen Davidoff

President & Chief Executive Officer

XORTX Therapeutics Inc.